Session » Vasculitis – Non-ANCA-Associated & Related Disorders Poster I: Giant Cell Arteritis & Polymyalgia Rheumatica (1391–1419)

Date: Monday, November 8, 2021

Time: 8:30AM-10:30AM

Meeting: ACR Convergence 2021

8:30AM-10:30AM: Abstract Number: 1398

Adrenal Insufficiency After Glucocorticoid Treatment of Giant Cell Arteritis

8:30AM-10:30AM: Abstract Number: 1393

All-cause Mortality in a Hospital Ascertained Cohort with Giant Cell Arteritis: A Longitudinal Population-level Data Linkage Cohort Study

8:30AM-10:30AM: Abstract Number: 1400

Analyses of Plasma Inflammatory Proteins Reveal Biomarkers Predictive of Subsequent Development of Giant Cell Arteritis; A Nested Case-Control Study

8:30AM-10:30AM: Abstract Number: 1392

Assessment of a Patient Self-Report Frailty Tool in Patients with Polymyalgia Rheumatica

8:30AM-10:30AM: Abstract Number: 1396

Baricitinib in Relapsing Giant Cell Arteritis: A Prospective Open-Label Single-Institution Study

8:30AM-10:30AM: Abstract Number: 1407

Characterization of Synovial Fluid T Cells in Polymyalgia Rheumatica: Implication of Th1 and Tc1 Effector Memory Profiles

8:30AM-10:30AM: Abstract Number: 1409

Clinical Features at Disease Onset of Different Subsets of Large-vessel-giant Cell Arteritis in a Monocentric Cohort of 100 Patients

8:30AM-10:30AM: Abstract Number: 1402

Clinical, Laboratory and Imaging Outcomes in Tocilizumab-Treated Patients with Large Vessel-Giant Cell Arteritis According to Early Onset Therapy

8:30AM-10:30AM: Abstract Number: 1411

Decreased Use of Ultrasound Fast-track Pathways of Giant Cell Arteritis Due to COVID-19 Pandemic: A Potential Risk for Permanent Visual Loss

8:30AM-10:30AM: Abstract Number: 1419

Development and Validation of a Patient Reported Outcome Measure for Giant Cell Arteritis

8:30AM-10:30AM: Abstract Number: 1416

Dysregulated Glucose Metabolism and Dyslipidemia in GCA and PMR Patients at Diagnosis

8:30AM-10:30AM: Abstract Number: 1405

Effectiveness of Tocilizumab in Cranial and Extracranial Phenotypes of Giant Cell Arteritis: Multicenter Study of 471 Cases

8:30AM-10:30AM: Abstract Number: 1412

Effectiveness of Tocilizumab in the Visual Involvement of Giant Cell Arteritis: Multicenter Study of 471 Patients of Clinical Practice

8:30AM-10:30AM: Abstract Number: 1403

Giant Cell Arteritis Subtypes: Data from the ARTESER Registry

8:30AM-10:30AM: Abstract Number: 1406

Incidence and General Clinical Features of Giant Cell Arteritis in the ARTESER Multicenter Study

8:30AM-10:30AM: Abstract Number: 1404

Lower Frequency of Comorbidities Prior to Onset of Giant Cell Arteritis; A Population-based Study

8:30AM-10:30AM: Abstract Number: 1417

Machine Learning Enhances the Identification of GCA from Its Mimics Based on Clinical Factors

8:30AM-10:30AM: Abstract Number: 1418

Patient Reported Outcomes on Quality of Life in Patients with Giant Cell Arteritis and Polymyalgia Rheumatica

8:30AM-10:30AM: Abstract Number: 1410

Predictors of Relapse in Giant-Cell Arteritis: A Retrospective Single Center Analysis

8:30AM-10:30AM: Abstract Number: 1391

Rituximab Is Superior to Placebo in Polymyalgia Rheumatica Patients: A Double Blind Randomized Controlled Proof of Principle Trial

8:30AM-10:30AM: Abstract Number: 1415

Temporal Artery Biopsy Reports Can Be Accurately Classified by Artificial Intelligence

8:30AM-10:30AM: Abstract Number: 1414

The Current State of Expedited Referral Systems Incorporating Vasculitis Ultrasound for the Diagnosis of Giant Cell Arteritis in Rheumatology Practices in the United States

8:30AM-10:30AM: Abstract Number: 1413

Tocilizumab in Combination with 8 Weeks of Prednisone for Giant Cell Arteritis

8:30AM-10:30AM: Abstract Number: 1408

Treatment of Giant Cell Arteritis in the ARTESER Multicenter Study of 1675 Patients

8:30AM-10:30AM: Abstract Number: 1397

Treatment of Giant Cell Arteritis with Tocilizumab: A Retrospective Cohort Study of 119 Patients

8:30AM-10:30AM: Abstract Number: 1395

Utility and Validity of the Southend Pretest Probability Score (SPTPS) in a Giant Cell Arteritis Fast Track Clinic: Analysis in a Spanish Cohort of 297 Patients

8:30AM-10:30AM: Abstract Number: 1401

Utility of CRP and ESR in the Assessment of Giant Cell Arteritis Relapse in a Phase 2 Trial of Mavrilimumab

8:30AM-10:30AM: Abstract Number: 1399

Validation of a Giant Cell Arteritis Probability Score

8:30AM-10:30AM: Abstract Number: 1394

Vascular Ultrasound for Giant Cell Arteritis: An Effective Diagnostic Modality for a Fast Track Clinic in the United States

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].